SYN 2869

Drug Profile

SYN 2869

Latest Information Update: 30 Nov 2004

Price : $50

At a glance

  • Originator NAEJA Pharmaceutical
  • Class Antifungals; Piperazines; Triazoles
  • Mechanism of Action 14-alpha demethylase inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.


Highest Development Phases

  • Discontinued Mycoses

Most Recent Events

  • 30 Nov 2004 Discontinued - Preclinical for Mycoses in Japan (PO)
  • 30 Nov 2004 Discontinued - Preclinical for Mycoses in Canada (PO)
  • 04 Oct 2004 Essential Therapeutics has closed down
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top